Liminatus Pharma, Inc.
LIMN
$1.28
-$0.03-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 1.12M | -- | 167.00K | 195.10K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | 300.00 | -- | -- | |
| Total Operating Expenses | 1.12M | 300.00 | 167.00K | 909.20K | |
| Operating Income | -1.12M | -300.00 | -167.00K | -909.20K | |
| Income Before Tax | 113.30K | -300.00 | -229.00K | -961.20K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 113.30K | -300.00 | -229.00K | -961.20K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 113.30K | -300.00 | -229.00K | -961.20K | |
| EBIT | -1.12M | -300.00 | -167.00K | -909.20K | |
| EBITDA | -1.12M | -- | -- | -- | |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.05 | |
| Normalized Basic EPS | -0.03 | 0.00 | 0.00 | -0.03 | |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.05 | |
| Normalized Diluted EPS | -0.03 | 0.00 | 0.00 | -0.03 | |
| Average Basic Shares Outstanding | 23.30M | 26.01M | 112.22M | 17.50M | |
| Average Diluted Shares Outstanding | 23.30M | 26.01M | 112.22M | 17.50M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |